Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial

Topics Coronavirus | Pfizer


FRANKFURT (Reuters) - Pfizer's German development partner BioNTech on Thursday joined other leading COVID-19 vaccine developers in ruling out participation in British plans to test experimental inoculations by deliberately infecting trial volunteers. "BioNTech's vaccine candidate is not part of this study," a spokeswoman said.

Britain is planning to host so-called "challenge trials", the Financial Times cited people involved in the project as saying. Britain said it was working with partners on the potential.

This article is no longer available in our repository.

There could be multiple reasons for this.